Eli Lilly and Company (NYSE:LLY) Major Shareholder Sells $12,855,409.50 in Stock

Eli Lilly and Company (NYSE:LLYGet Rating) major shareholder Lilly Endowment Inc sold 41,610 shares of the stock in a transaction dated Wednesday, May 25th. The stock was sold at an average price of $308.95, for a total transaction of $12,855,409.50. Following the transaction, the insider now directly owns 105,212,200 shares in the company, valued at approximately $32,505,309,190. The transaction was disclosed in a filing with the SEC, which is available through this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Lilly Endowment Inc also recently made the following trade(s):

  • On Monday, May 23rd, Lilly Endowment Inc sold 118,856 shares of Eli Lilly and stock. The stock was sold at an average price of $302.73, for a total transaction of $35,981,276.88.
  • On Wednesday, May 18th, Lilly Endowment Inc sold 700 shares of Eli Lilly and stock. The stock was sold at an average price of $302.00, for a total value of $211,400.00.
  • On Monday, May 16th, Lilly Endowment Inc sold 80,761 shares of Eli Lilly and stock. The shares were sold at an average price of $302.53, for a total value of $24,432,625.33.
  • On Friday, April 8th, Lilly Endowment Inc sold 139,045 shares of Eli Lilly and stock. The shares were sold at an average price of $310.79, for a total value of $43,213,795.55.
  • On Wednesday, April 6th, Lilly Endowment Inc sold 51,851 shares of Eli Lilly and stock. The shares were sold at an average price of $300.92, for a total transaction of $15,603,002.92.
  • On Monday, April 4th, Lilly Endowment Inc sold 39,393 shares of Eli Lilly and stock. The shares were sold at an average price of $293.15, for a total transaction of $11,548,057.95.
  • On Friday, April 1st, Lilly Endowment Inc sold 165,376 shares of Eli Lilly and stock. The stock was sold at an average price of $292.38, for a total transaction of $48,352,634.88.
  • On Wednesday, March 30th, Lilly Endowment Inc sold 2,500 shares of Eli Lilly and stock. The stock was sold at an average price of $292.03, for a total transaction of $730,075.00.
  • On Monday, March 28th, Lilly Endowment Inc sold 7,538 shares of Eli Lilly and stock. The shares were sold at an average price of $292.15, for a total transaction of $2,202,226.70.
  • On Monday, March 21st, Lilly Endowment Inc sold 35,245 shares of Eli Lilly and stock. The shares were sold at an average price of $292.43, for a total transaction of $10,306,695.35.

Shares of Eli Lilly and stock traded up $2.51 during trading hours on Thursday, hitting $309.52. The company’s stock had a trading volume of 61,904 shares, compared to its average volume of 2,931,045. Eli Lilly and Company has a 1-year low of $195.50 and a 1-year high of $314.00. The business has a fifty day moving average of $293.92 and a 200 day moving average of $268.67. The company has a market capitalization of $294.09 billion, a PE ratio of 45.48, a P/E/G ratio of 2.27 and a beta of 0.40. The company has a quick ratio of 0.98, a current ratio of 1.27 and a debt-to-equity ratio of 1.60.

Eli Lilly and (NYSE:LLYGet Rating) last released its quarterly earnings results on Thursday, April 28th. The company reported $2.62 earnings per share for the quarter, beating analysts’ consensus estimates of $2.32 by $0.30. The business had revenue of $7.81 billion during the quarter, compared to analyst estimates of $7.29 billion. Eli Lilly and had a net margin of 20.90% and a return on equity of 97.58%. The business’s revenue was up 14.8% on a year-over-year basis. During the same period last year, the business earned $1.87 EPS. On average, sell-side analysts anticipate that Eli Lilly and Company will post 8.25 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, June 10th. Investors of record on Monday, May 16th will be issued a dividend of $0.98 per share. This represents a $3.92 dividend on an annualized basis and a yield of 1.27%. The ex-dividend date is Friday, May 13th. Eli Lilly and’s payout ratio is 58.07%.

LLY has been the subject of a number of recent research reports. Mizuho raised their target price on shares of Eli Lilly and from $315.00 to $356.00 in a report on Monday, May 2nd. StockNews.com raised shares of Eli Lilly and from a “buy” rating to a “strong-buy” rating in a research report on Wednesday. Bank of America increased their price objective on shares of Eli Lilly and from $300.00 to $315.00 in a research report on Thursday, March 17th. Morgan Stanley increased their price objective on shares of Eli Lilly and from $364.00 to $369.00 in a research report on Friday, April 29th. Finally, SVB Leerink initiated coverage on shares of Eli Lilly and in a research report on Monday. They issued an “outperform” rating and a $341.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, three have given a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $304.58.

Hedge funds have recently made changes to their positions in the business. Vestmark Advisory Solutions Inc. lifted its position in shares of Eli Lilly and by 3.1% in the 4th quarter. Vestmark Advisory Solutions Inc. now owns 12,157 shares of the company’s stock worth $3,358,000 after buying an additional 364 shares during the last quarter. Wedbush Securities Inc. lifted its position in Eli Lilly and by 110.1% in the 4th quarter. Wedbush Securities Inc. now owns 11,235 shares of the company’s stock valued at $3,103,000 after purchasing an additional 5,887 shares during the last quarter. Lincoln National Corp lifted its position in Eli Lilly and by 4.9% in the 4th quarter. Lincoln National Corp now owns 9,656 shares of the company’s stock valued at $2,667,000 after purchasing an additional 455 shares during the last quarter. Cadence Bank NA lifted its position in Eli Lilly and by 0.5% in the 4th quarter. Cadence Bank NA now owns 10,690 shares of the company’s stock valued at $2,953,000 after purchasing an additional 58 shares during the last quarter. Finally, Sigma Planning Corp lifted its position in Eli Lilly and by 12.2% in the 4th quarter. Sigma Planning Corp now owns 16,879 shares of the company’s stock valued at $4,662,000 after purchasing an additional 1,829 shares during the last quarter. 82.75% of the stock is owned by institutional investors.

About Eli Lilly and (Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Featured Articles

Insider Buying and Selling by Quarter for Eli Lilly and (NYSE:LLY)

Want More Great Investing Ideas?

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.